

**CHARTTRENDS®: RHEUMATOID ARTHRITIS 2011**

*This report is an annual publication that provides comprehensive insight into the management of rheumatoid arthritis (RA) patients being treated with biologics based on actual patient level data. ChartTrends are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.*

**SAMPLE FRAME AND METHODOLOGY**

Over 200 rheumatologists will complete patient audits for four to seven of their RA patients who are being treated with a biologic agent: Actemra, Cimzia, Enbrel, Humira, Orenzia, Remicade, Rituxan, and Simponi

In addition to completing the patient audits, each rheumatologist will complete a profile survey regarding attitudes, treatment patterns and practice demographics

The audit is HIPPA certified

**PRODUCT COVERAGE**

Approved: Actemra, Cimzia, Enbrel, Humira, Orenzia, Remicade, Rituxan, and Simponi

In development: Ofatumumab, Tofacitinib, and Fostamatinib

**RELATED REPORTS**

TreatmentTrends®: RA (US)

TreatmentTrends®: RA (E5)

ChartTrends®: RA (E5)

**PRICE**

**\$59,000**

**PROJECT OBJECTIVES**

- Understand the demographics of RA patients
  - Underlying cause of RA, co-morbidities, common medications (DMARDs and others) patient demographics, patient origination, presentation at diagnosis, biologic initiation and present
- Understand the standard of care for RA patients
  - Frequency of office visits, laboratory assessments, and radiographic assessments
- Understand the selection process for RA treatments and medications
  - What factors drive brand selection (i.e. co-morbidities, concomitant therapies, lab value ranges, disease awareness attitudes, etc.) for first and later line use?
- Understand rheumatologists' attitude toward current RA medications
  - Identify issues that are impacting the way Rheumatologists manage RA patients
  - Identify characteristics that correlate with certain treatment approaches by comparing survey responses with actual treatment records

**DELIVERABLES**

- Final report in PowerPoint format
- Complete set of frequency tables, summary statistics and cross tabulations
- Database containing de-identified patient audit data in SPSS or excel
- Clients purchasing prior to fielding will have to opportunity to include up to 5 proprietary questions in the physician profile section

**REPORT DATES**

Date comments/proprietary questions are due	Field date	Publication date
September 30, 2011	October 14, 2011	December 20, 2011